Scholarlink

<p>The aminoglycosides are essential drugs in the treatment of multidrug-resistant tuberculosis. Antibiotic resistance of <i>Mycobacterium tuberculosis</i> is a major public health concern worldwide. Therefore, it is of great significance to characterize the mutations by which susceptible <i>M. tuberculosis</i> evolves into drug resistance. A total of 110 clinical isolates of MDR-TB were used for Whole-genome sequencing (WGS) and phenotypic drug susceptibility testing to aminoglycosides, including amikacin, kanamycin, and streptomycin. Among 110 clinical MDR-TB strains, 7 (6.36%) were cross-resistant to amikacin and kanamycin, and 81 (73.64%) were resistant to streptomycin. The resistance rates to rifabutin, streptomycin, moxifloxacin, ofloxacin, and ethambutol were observed in 79.09%, 73.64%,35.45%, 34.55%, and 30.91%, respectively. Among the 81 MDR-TB strains resistant to streptomycin, the MIC values of streptomycin against MDR-TB showed the following distribution: 61 strains (75.31%) demonstrated resistance with MICs ≥ 32&#xa0;µg/ml. The <i>rrs</i> gene mutations were detected in 6 (85.71%; 6/7) of the amikacin/kanamycin-resistant isolates, with the most frequent mutation being A1401G. Mutations in the <i>eis</i> promoter were identified at two positions in 3 amikacin/kanamycin-susceptible and streptomycin-resistant isolates (-10G &gt; A and − 37G &gt; T). In 80.25% (65 out of 81) of streptomycin-resistant MDR-TB isolates, two types of amino acid substitutions associated with <i>rpsL</i> mutations were identified. K43R was observed in 86.15% of isolates with mutations in <i>rpsL</i>, followed by K88R at 13.85%. In conclusion, current critical concentration methods and the design of molecular diagnostics need to be revisited to provide more accurate assessments of streptomycin resistance for <i>rspL</i> mutation-bearing isolates.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Key resistance-associated mutations in multidrug-resistant tuberculosis: a genomic study from Shanghai, China, with a focus on aminoglycosides

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月30日

查看全文
  • Yinjuan Guo,
  • Jinghui Yang,
  • Hongxiu Wang,
  • Wei Sha,
  • Fangyou Yu

摘要

The aminoglycosides are essential drugs in the treatment of multidrug-resistant tuberculosis. Antibiotic resistance of Mycobacterium tuberculosis is a major public health concern worldwide. Therefore, it is of great significance to characterize the mutations by which susceptible M. tuberculosis evolves into drug resistance. A total of 110 clinical isolates of MDR-TB were used for Whole-genome sequencing (WGS) and phenotypic drug susceptibility testing to aminoglycosides, including amikacin, kanamycin, and streptomycin. Among 110 clinical MDR-TB strains, 7 (6.36%) were cross-resistant to amikacin and kanamycin, and 81 (73.64%) were resistant to streptomycin. The resistance rates to rifabutin, streptomycin, moxifloxacin, ofloxacin, and ethambutol were observed in 79.09%, 73.64%,35.45%, 34.55%, and 30.91%, respectively. Among the 81 MDR-TB strains resistant to streptomycin, the MIC values of streptomycin against MDR-TB showed the following distribution: 61 strains (75.31%) demonstrated resistance with MICs ≥ 32 µg/ml. The rrs gene mutations were detected in 6 (85.71%; 6/7) of the amikacin/kanamycin-resistant isolates, with the most frequent mutation being A1401G. Mutations in the eis promoter were identified at two positions in 3 amikacin/kanamycin-susceptible and streptomycin-resistant isolates (-10G > A and − 37G > T). In 80.25% (65 out of 81) of streptomycin-resistant MDR-TB isolates, two types of amino acid substitutions associated with rpsL mutations were identified. K43R was observed in 86.15% of isolates with mutations in rpsL, followed by K88R at 13.85%. In conclusion, current critical concentration methods and the design of molecular diagnostics need to be revisited to provide more accurate assessments of streptomycin resistance for rspL mutation-bearing isolates.